



Zanzalintinib in Combination With Immune Checkpoint Inhibitors: Design of the Renal Cell Carcinoma Expansion Stage Cohorts in STELLAR-002

Robert J. Motzer,¹ Toni K. Choueiri,² Benjamin Garmezy,³ Bert O'Neil,⁴ Joel Michalski,⁵ Pedro Barata,⁶ Aung Bajaj,⁷ Jad Chahoud,⁸ Mohan Liu,⁹ Fiona Xu,¹⁰ Svetlana Andrianova,¹⁰ Neil Shah,¹ Bradley McGregor²


¹Memorial Sloan Kettering Cancer Center, New York, NY, USA; ²Dana-Farber Cancer Institute, Boston, MA, USA; ³Sarah Cannon Research Institute at Tennessee Oncology, PLLC, Nashville, TN, USA; ⁴Community North Cancer Center, Indianapolis, IN, USA; ⁵Nebraska Cancer Specialists, Omaha, NE, USA; ⁶University Hospitals Seidman Cancer Center, Cleveland, OH, USA; ⁷Arizona Oncology, Tucson, AZ, USA; ⁸Moffitt Cancer Center, Tampa, FL, USA; ⁹Bristol Myers Squibb, New York, NY, USA; ¹⁰Exelixis, Inc., Alameda, CA, USA

BOSTON, MASS | JULY 13-14, 2023

Background


Zanzalintinib as a Single Agent

- Inhibits tumor growth and angiogenesis through multi-targeted tyrosine kinase receptor inhibition (VEGFR, MET, TAM kinases)¹
- Promising preliminary clinical activity and manageable safety profile of zanzalintinib has been observed in RCC²




Zanzalintinib in Combination With ICIs

- Activation of VEGFR, MET, and TAM kinases promotes immunosuppressive activity of Tregs, MDSCs, and macrophages, and inhibits antigen presentation¹
- Enhance response to ICI by promoting an immune-permissive environment³



1. Hsu J, et al. *Mol Cancer Ther.* 2023;22:179–191. 2. Sharma MR, et al. *Ann Oncol.* 2022;33(suppl 7):Abstract 481P. 3. Bergerot P, et al. *Mol Cancer Ther.* 2019;18:2185–2193.

STELLAR-002 Study Design



Dose-escalation stage will determine the recommended doses for the expansion stage.

*Combination therapy consisting of a PD-1/PD-L1 inhibitor + VEGFR-TKI or a PD-1 + CTLA-4 inhibitor. Prior triplets including VEGFR-TKI, PD-1, and CTLA-4 inhibitors are not allowed. [†]Chromophobe, renal medullary carcinoma, and pure collecting duct nccRCC are excluded.

Summary & Future Directions

- The phase 1b STELLAR-002 study (NCT05176483) is evaluating the safety and clinical activity of zanzalintinib alone and in combination with nivolumab, nivolumab + ipilimumab, and nivolumab + relatlimab in patients with advanced solid tumors, including ccRCC and nccRCC
- STELLAR-002 is currently ongoing and enrolling patients from sites in North America, Europe, and the Asia-Pacific regions
- Future directions
 - STELLAR-304 (NCT05678673), an open-label, randomized, phase 3 study, is also ongoing and is evaluating the efficacy and safety of zanzalintinib + nivolumab versus sunitinib in first-line nccRCC¹
 - Additional clinical trials are planned based on STELLAR-002 expansion cohort results

STELLAR-304

- Unresectable, locally advanced or metastatic nccRCC (papillary, unclassified, or translocation-associated)
- No prior systemic anticancer therapy



STELLARclinicaltrials.com

1. Exelixis, Inc. ClinicalTrials.gov identifier: NCT05678673. <https://clinicaltrials.gov/ct2/show/NCT05678673>.